Perioperative medicine and UK plc

G. L. Ackland (Corresponding Author), H. F. Galley, B. Shelley, D. G. Lambert

Research output: Contribution to journalEditorial

Abstract

In March and May 2018, two open meetings were convened under the auspices of the National Institute of Academic Anaesthesia (NIAA) and National Institute of Health Research (NIHR) to consider how both clinical and non-clinical academics, research active National Health Service (NHS) clinicians, and industry representatives can continue to build on the investment underpinned by the NIAA in discovery science and experimental medicine. As an exemplar for drug discovery and experimental medicine, perioperative medicine has been transformed by extraordinary technological and pharmacological breakthroughs in both academia and industry, including Mapleson breathing circuits,1 propofol, the laryngeal mask airway,2 remifentanil,3 and sugammadex,4 to name a few. These advances have occurred, in comparison with many other specialties, at an astonishing pace. It is easy to overlook the impact of these huge technological leaps from the bench that have transformed anaesthetic—and wider—medical practice. Such innovation from industry, academia and the NHS are exemplars for the UK's ambition to secure health–life sciences as a pivotal industrial sector. Having reached, at least from a historical perspective, a likely plateau in progress in terms of technical equipment, there is an undeniable role for a new model of bi-directional, bedside-to-bench research contributing within the sphere of perioperative medicine, critical care, and pain medicine. As a potentially even more exciting era is emerging from both industrial and technological perspectives, here we consider the drivers that require discovery science and experimental medicine in anaesthesia to manoeuvre back into the fast lane of biomedical discovery.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalBritish Journal of Anaesthesia
Volume122
Issue number1
Early online date26 Oct 2018
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Biomedical Research
Industry
Anesthesia
Medicine
National Health Programs
Research
Laryngeal Masks
National Institutes of Health (U.S.)
Propofol
Drug Discovery
Critical Care
Names
Respiration
Pharmacology
Pain
Equipment and Supplies
remifentanil
Sugammadex

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Perioperative medicine and UK plc. / Ackland, G. L. (Corresponding Author); Galley, H. F.; Shelley, B.; Lambert, D. G.

In: British Journal of Anaesthesia, Vol. 122, No. 1, 01.01.2019, p. 3-7.

Research output: Contribution to journalEditorial

Ackland, G. L. ; Galley, H. F. ; Shelley, B. ; Lambert, D. G. / Perioperative medicine and UK plc. In: British Journal of Anaesthesia. 2019 ; Vol. 122, No. 1. pp. 3-7.
@article{6080b30862944a7bb34d63249c51bbb5,
title = "Perioperative medicine and UK plc",
abstract = "In March and May 2018, two open meetings were convened under the auspices of the National Institute of Academic Anaesthesia (NIAA) and National Institute of Health Research (NIHR) to consider how both clinical and non-clinical academics, research active National Health Service (NHS) clinicians, and industry representatives can continue to build on the investment underpinned by the NIAA in discovery science and experimental medicine. As an exemplar for drug discovery and experimental medicine, perioperative medicine has been transformed by extraordinary technological and pharmacological breakthroughs in both academia and industry, including Mapleson breathing circuits,1 propofol, the laryngeal mask airway,2 remifentanil,3 and sugammadex,4 to name a few. These advances have occurred, in comparison with many other specialties, at an astonishing pace. It is easy to overlook the impact of these huge technological leaps from the bench that have transformed anaesthetic—and wider—medical practice. Such innovation from industry, academia and the NHS are exemplars for the UK's ambition to secure health–life sciences as a pivotal industrial sector. Having reached, at least from a historical perspective, a likely plateau in progress in terms of technical equipment, there is an undeniable role for a new model of bi-directional, bedside-to-bench research contributing within the sphere of perioperative medicine, critical care, and pain medicine. As a potentially even more exciting era is emerging from both industrial and technological perspectives, here we consider the drivers that require discovery science and experimental medicine in anaesthesia to manoeuvre back into the fast lane of biomedical discovery.",
author = "Ackland, {G. L.} and Galley, {H. F.} and B. Shelley and Lambert, {D. G.}",
note = "GLA is supported by British Journal of Anaesthesia/Royal College of Anaesthetists basic science Career Development award, British Oxygen Company research chair grant in anaesthesia from the Royal College of Anaesthetists and British Heart Foundation Programme Grant (RG/14/4/30736). HFG: funded by the Association of Anaesthetists of Great Britain and Ireland, the British Journal of Anaesthesia/Royal College of Anaesthetists and the Melville Trust. BGS: Chief Scientific Officer/NHS Research Scotland Career Research Fellow award. DGL: BBSRC; British Journal of Anaesthesia PhD studentship.",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bja.2018.09.023",
language = "English",
volume = "122",
pages = "3--7",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "ELSEVIER APPL SCI PUBL LTD",
number = "1",

}

TY - JOUR

T1 - Perioperative medicine and UK plc

AU - Ackland, G. L.

AU - Galley, H. F.

AU - Shelley, B.

AU - Lambert, D. G.

N1 - GLA is supported by British Journal of Anaesthesia/Royal College of Anaesthetists basic science Career Development award, British Oxygen Company research chair grant in anaesthesia from the Royal College of Anaesthetists and British Heart Foundation Programme Grant (RG/14/4/30736). HFG: funded by the Association of Anaesthetists of Great Britain and Ireland, the British Journal of Anaesthesia/Royal College of Anaesthetists and the Melville Trust. BGS: Chief Scientific Officer/NHS Research Scotland Career Research Fellow award. DGL: BBSRC; British Journal of Anaesthesia PhD studentship.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In March and May 2018, two open meetings were convened under the auspices of the National Institute of Academic Anaesthesia (NIAA) and National Institute of Health Research (NIHR) to consider how both clinical and non-clinical academics, research active National Health Service (NHS) clinicians, and industry representatives can continue to build on the investment underpinned by the NIAA in discovery science and experimental medicine. As an exemplar for drug discovery and experimental medicine, perioperative medicine has been transformed by extraordinary technological and pharmacological breakthroughs in both academia and industry, including Mapleson breathing circuits,1 propofol, the laryngeal mask airway,2 remifentanil,3 and sugammadex,4 to name a few. These advances have occurred, in comparison with many other specialties, at an astonishing pace. It is easy to overlook the impact of these huge technological leaps from the bench that have transformed anaesthetic—and wider—medical practice. Such innovation from industry, academia and the NHS are exemplars for the UK's ambition to secure health–life sciences as a pivotal industrial sector. Having reached, at least from a historical perspective, a likely plateau in progress in terms of technical equipment, there is an undeniable role for a new model of bi-directional, bedside-to-bench research contributing within the sphere of perioperative medicine, critical care, and pain medicine. As a potentially even more exciting era is emerging from both industrial and technological perspectives, here we consider the drivers that require discovery science and experimental medicine in anaesthesia to manoeuvre back into the fast lane of biomedical discovery.

AB - In March and May 2018, two open meetings were convened under the auspices of the National Institute of Academic Anaesthesia (NIAA) and National Institute of Health Research (NIHR) to consider how both clinical and non-clinical academics, research active National Health Service (NHS) clinicians, and industry representatives can continue to build on the investment underpinned by the NIAA in discovery science and experimental medicine. As an exemplar for drug discovery and experimental medicine, perioperative medicine has been transformed by extraordinary technological and pharmacological breakthroughs in both academia and industry, including Mapleson breathing circuits,1 propofol, the laryngeal mask airway,2 remifentanil,3 and sugammadex,4 to name a few. These advances have occurred, in comparison with many other specialties, at an astonishing pace. It is easy to overlook the impact of these huge technological leaps from the bench that have transformed anaesthetic—and wider—medical practice. Such innovation from industry, academia and the NHS are exemplars for the UK's ambition to secure health–life sciences as a pivotal industrial sector. Having reached, at least from a historical perspective, a likely plateau in progress in terms of technical equipment, there is an undeniable role for a new model of bi-directional, bedside-to-bench research contributing within the sphere of perioperative medicine, critical care, and pain medicine. As a potentially even more exciting era is emerging from both industrial and technological perspectives, here we consider the drivers that require discovery science and experimental medicine in anaesthesia to manoeuvre back into the fast lane of biomedical discovery.

UR - http://www.scopus.com/inward/record.url?scp=85055668421&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/perioperative-medicine-uk-plc

U2 - 10.1016/j.bja.2018.09.023

DO - 10.1016/j.bja.2018.09.023

M3 - Editorial

VL - 122

SP - 3

EP - 7

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 1

ER -